Publication | Open Access
Cannabidiol Acts at 5-HT1A Receptors in the Human Brain: Relevance for Treating Temporal Lobe Epilepsy
55
Citations
40
References
2020
Year
Experimental evidence indicates that cannabidiol (CBD) induces anxiolytic and antiepileptic effects through the activation of 5-HT<sub>1A</sub> receptors. These receptors are coupled to G<sub>i/o</sub> proteins and induce inhibitory effects. At present, the interaction of CBD with 5-HT<sub>1A</sub> receptors in the human brain is unknown. The aim of this study focused on evaluating the interaction between CBD and 5-HT<sub>1A</sub> receptors in cell membranes obtained from the hippocampus and temporal neocortex of autopsies and patients with drug-resistant mesial temporal lobe epilepsy (DR-MTLE). Cell membranes were isolated from the hippocampus and temporal neocortex of a group of patients with DR-MTLE who were submitted to epilepsy surgery (<i>n</i> = 11) and from a group of autopsies (<i>n</i> = 11). The [<sup>3</sup>H]-8-OH-DPAT binding assay was used to determine the pharmacological interaction of CBD with 5-HT<sub>1A</sub> receptors. The [<sup>35</sup>S]-GTPγS assay was used to investigate the CBD-induced activation of G<sub>i/o</sub> proteins through its action on 5-HT<sub>1A</sub> receptors.The CBD affinity (p<i>K</i> <sub>i</sub>) for 5-HT<sub>1A</sub> receptors was similar for autopsies and patients with DR-MTLE (hippocampus: 4.29 and 4.47, respectively; temporal neocortex: 4.67 and 4.74, respectively). Concerning the [<sup>35</sup>S]-GTPγS assay, no statistically significant changes were observed for both hippocampal and neocortical tissue (<i>p</i> > 0.05) at low CBD concentrations (1 pM to 10 μM). In contrast, at high concentrations (100 μM), CBD reduced the constitutive activity of G<sub>i/o</sub> proteins of autopsies and DR-MTLE patients (hippocampus: 39.2% and 39.6%, respectively; temporal neocortex: 35.2% and 24.4%, respectively). These changes were partially reversed in the presence of WAY-100635, an antagonist of 5-HT<sub>1A</sub> receptors, in the autopsy group (hippocampus, 59.8%, <i>p</i> < 0.0001; temporal neocortex, 71.5%, <i>p</i> < 0.0001) and the group of patients with DR-MTLE (hippocampus, 53.7%, <i>p</i> < 0.0001; temporal neocortex, 68.5%, <i>p</i> < 0.001). Our results show that CBD interacts with human 5-HT<sub>1A</sub> receptors of the hippocampus and temporal neocortex. At low concentrations, the effect of CBD upon G<sub>i/o</sub> protein activation is limited. However, at high concentrations, CBD acts as an inverse agonist of 5-HT<sub>1A</sub> receptors. This effect could modify neuronal excitation and epileptic seizures in patients with DR-MTLE.
| Year | Citations | |
|---|---|---|
Page 1
Page 1